Brandon BioCatalyst CUREator+ Dementia and Cognitive Decline

The program aims to accelerate the translation and commercialisation of early-stage Australian medical research and innovations that improve or prolong the lives of people living with dementia, as well as the caregivers who support them.

Eligible innovations include:

• Therapeutics – a board range of traditional and emerging drug modalities
• Diagnostics – test and imaging technologies used to detect, monitor or support drug development
• Biomarkers – biological indicators (eg genetic variants) used to diagnose, predict or monitor disease and treatment response
• Medical devices – physical tools or components
• Digital health – software, sensors or connectivity that deliver therapeutic, diagnostic or assistive healthcare solutions

Grant funding of up to $5 million per project are available across two stages:

Stage 1: Funding between $1 million and $2.5 million, disbursed in aligned to commercially relevant milestones

Stage 2: Additional top-up funding of up to $5 million is available on a competitive basis for projects that meet their Stage 1 milestones

A cash contribution from the applicant is required.

Eligible applicants must be either:

• Australian small to medium size enterprise – a for-profit company with less than 200 employees, or
• Researchers, not-for-profit organisations or university technology transfer offices/IP holding companies – provided they are willing to incorporate as a for-profit Australian company, if successful.

Expression of interest applications close 10th July 2025.